A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of α-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)

Ming Zhong, Aijun Sun, Ting Xiao, Ge Yao, Ling Sang, Xia Zheng, Jinyan Zhang, Xuejuan Jin, Lei Xu, Wenlong Yang, Peng Wang, Kai Hu, Dingyu Zhang, Junbo GeFrontiers in Medicine 2022 · DOI

TL;DR

This study investigated the potential of alpha-lipoic acid (ALA) as a treatment for critically ill COVID-19 patients. While the small sample size limited statistical significance, ALA showed a trend towards improving organ function (SOFA score) and reducing mortality, suggesting it could be a promising adjunctive therapy worth further investigation.

What Problem Does This Paper Address?

The COVID-19 pandemic, caused by SARS-CoV-2, has overwhelmed healthcare systems globally, with a high mortality rate among critically ill patients. Effective treatments for severe COVID-19 remain limited. Pathological findings suggest that severe COVID-19 involves diffuse alveolar damage and a cytokine release syndrome (CRS), characterized by a sharp increase in pro-inflammatory cytokines. Additionally, viral infections can lead to increased production of reactive oxygen species (ROS), which contribute to organ damage and systemic inflammation. Therefore, strategies to regulate systemic inflammation and combat oxidative stress are crucial for treating critically ill COVID-19 patients. Alpha-lipoic acid (ALA), a known antioxidant, has demonstrated anti-inflammatory effects in other conditions, making it a potential candidate to alleviate these pathological processes in COVID-19.

Methods

This was a randomized, single-blind, group sequential, active-controlled trial conducted at JinYinTan Hospital in Wuhan, China, between February and March 2020. Seventeen critically ill COVID-19 patients were enrolled and randomly assigned in a 1:1 ratio to receive either:

  • Treatment Group: ALA (1200 mg/day, intravenous infusion) once daily for 7 days, in addition to standard care.
  • Control Group: Equal volume saline infusion (placebo) for 7 days, in addition to standard care.

Patients were monitored for 7 days of therapy and followed up for 30 days. The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score. The secondary outcome was all-cause mortality within 30 days. Statistical analysis included Kaplan-Meier methods for time-to-event endpoints, Cox regression models, and standard statistical tests for continuous and categorical variables.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • ALA's Dual Action Potential: The study highlights ALA's potential to combat COVID-19's severe manifestations through its dual antioxidant and anti-inflammatory properties. This is particularly relevant given the known roles of ROS and cytokine storms in COVID-19 pathogenesis.
  • Promising Trends Despite Small Sample Size: Even with a small cohort, the observed trends towards improved SOFA scores and reduced mortality in the ALA group are encouraging. This suggests that ALA might offer a tangible benefit, even if not statistically significant due to sample limitations.
  • The Challenge of Critically Ill Patient Recruitment: The study acknowledges the difficulty in recruiting critically ill patients, especially during a rapidly evolving epidemic. This is a common challenge in critical care research and underscores the need for innovative trial designs and international collaboration.

Key Results

  • SOFA Score: The average SOFA score increased by 1.7 points in the placebo group (from 4.3 to 6.0) and by 0.2 points in the ALA group (from 3.8 to 4.0) over 7 days. While this difference was not statistically significant (P = 0.36), it suggests a trend towards less organ function deterioration with ALA.
  • All-Cause Mortality: After 30 days, the all-cause mortality rate was 77.8% (7/9) in the placebo group and 37.5% (3/8) in the ALA group. This numerical difference, while not reaching statistical significance (P = 0.09), indicates a potentially lower mortality risk with ALA.
  • Safety: No unexpected drug-related adverse events were reported during the trial.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Size: The most significant limitation is the small number of enrolled patients (n=17). This severely restricts the statistical power to detect significant differences, even when trends are observed.
  • All-Cause Mortality as Secondary Outcome: Using all-cause mortality as a secondary outcome means that deaths due to secondary bacterial infections, common in critically ill patients, could confound the results and not solely reflect the primary SARS-CoV-2 insult.

Future work should focus on larger, multi-center clinical trials to validate these promising findings. Investigating ALA's role in preventing or mitigating cytokine storms and oxidative stress in critically ill COVID-19 patients is crucial. Further research could also explore optimal dosing and duration of ALA therapy.

Summary updated

Abstract

http://www.chictr.org.cn/showproj.aspx?proj=49534.
BibTeX
@inproceedings{zhong2022randomized,
  author = {Ming Zhong and Aijun Sun and Ting Xiao and Ge Yao and Ling Sang and Xia Zheng and Jinyan Zhang and Xuejuan Jin and Lei Xu and Wenlong Yang and Peng Wang and Kai Hu and Dingyu Zhang and Junbo Ge},
  title = {{A Randomized, Single-Blind, Group Sequential, Active-Controlled Study to Evaluate the Clinical Efficacy and Safety of α-Lipoic Acid for Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2021.566609},
}
Figure